Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Impedimed Limited ( (AU:IPD) ).
Impedimed Limited announced the issuance of 438,223 ordinary fully paid shares to its non-executive directors as part of the Non-Executive Director Share Plan, covering 30% of director fees for the quarter ending September 30, 2025. This move reflects the company’s ongoing commitment to aligning the interests of its directors with those of its shareholders, potentially impacting its market perception and stakeholder confidence positively.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on the development and distribution of non-invasive medical devices. The company specializes in bioimpedance spectroscopy, which is used for the clinical assessment of fluid status and tissue composition, primarily targeting healthcare providers and patients in need of monitoring for conditions such as lymphedema and heart failure.
Average Trading Volume: 1,825,698
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$77.37M
For detailed information about IPD stock, go to TipRanks’ Stock Analysis page.